valsartan has been researched along with Malignant Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Michaud, CJ; Trethowan, B | 1 |
| Hartner, A; Hilgers, KF; Mann, JF; Porst, M; Veelken, R | 1 |
2 other study(ies) available for valsartan and Malignant Hypertension
| Article | Year |
|---|---|
Valsartan Effective for Malignant Hypertension after Aortic Dissection with Renal Artery Involvement.
Topics: Adult; Antihypertensive Agents; Aortic Dissection; Humans; Hypertension, Malignant; Male; Renal Artery; Valsartan | 2018 |
Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Malignant; Hypertension, Renovascular; Immunohistochemistry; Kidney; Macrophages; Male; Nephritis; Organ Size; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Survival Rate; Tetrazoles; Valine; Valsartan | 2001 |